Abstract: Cancer is the second leading cause of mortality worldwide despite tremendous advances in treatment. The promise of precision oncology depends on accurate characterization of tumor mutations and subsequent therapy selection….
Read More
The particularly interdisciplinary nature of human microbiome research makes the organization and reporting of results spanning epidemiology, biology, bioinformatics, translational medicine and statistics a challenge. Commonly used reporting guidelines for…
Advancing NGS quality control to enable measurement of actionable mutations in circulating tumor DNA
Despite an increasing demand for precision medicine enabled by NGS measurement of actionable mutations in circulating tumor DNA (ctDNA) specimens, the ability to reliably measure and report low-frequency mutations using…
Reproducibility is essential to open science, as there is limited relevance for findings that can not be reproduced by independent research groups, regardless of its validity. It is therefore crucial…
The lack of samples for generating standardized DNA datasets for setting up a sequencing pipeline or benchmarking the performance of different algorithms limits the implementation and uptake of cancer genomics….
Clinical applications of precision oncology require accurate tests that can distinguish true cancer-specific mutations from errors introduced at each step of next-generation sequencing (NGS). To date, no bulk sequencing study…
Executive with Extensive Legal Expertise in Life Sciences Strengthens Leadership Team CAMBRIDGE, Mass., July 20, 2021— Immuneering Corporation (“Immuneering”), a private biopharmaceutical company advancing a robust pipeline of oncology and…
Former Chief Financial Officer of Harvard University Strengthens Board with Financial Expertise and Considerable Board Experience CAMBRIDGE, Mass., July 14, 2021 (GLOBE NEWSWIRE) — Immuneering Corporation (“Immuneering”), a private…
Introduction: Daratumumab (DARA) is a human IgG1κ monoclonal antibody that binds with high affinity to a unique epitope on CD38. DARA monotherapy has shown promising activity in relapsed and/or refractory…
CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) — Immuneering Corporation (“Immuneering”) today announced the addition of Laurie Keating to its board of directors. Ms. Keating brings more than 25 years…
